Celanese (NYSE:CE) has supplied cures in a bid to deal with antitrust issues raised by the European Union associated to its proposed $11B acquisition of DuPont’s (DD) mobility and supplies enterprise, in keeping with a European Fee submitting Wednesday that didn’t provide particulars.
The European Fee on Competitors will search suggestions from rivals and clients earlier than deciding by October 11 whether or not to just accept the cures or demand extra; it might open a four-month investigation if it has critical issues.
Celanese (CE) introduced the acquisition in February, however traders and analysts questioned the deal’s prices whereas appreciating the long-term advantages to the corporate.